Advertisement

Neurochemical Research

, Volume 41, Issue 7, pp 1774–1783 | Cite as

Differential Expression of Adenosine P1 Receptor ADORA1 and ADORA2A Associated with Glioma Development and Tumor-Associated Epilepsy

  • Jun Huang
  • Ming-Na Chen
  • Juan Du
  • Hao Liu
  • Yu-Jiao He
  • Guo-Liang Li
  • Shu-Yu Li
  • Wei-Ping Liu
  • Xiao-Yan LongEmail author
Original Paper

Abstract

Level of adenosine, an endogenous astrocyte-based neuromodulator, is primarily regulated by adenosine P1 receptors. This study assessed expression of adenosine P1 receptors, ADORA1 (adenosine A1 receptor) and ADORA2A (adenosine A2a receptor) and their association with glioma development and epilepsy in glioma patients. Expression of ADORA1/ADORA2A was assessed immunohistochemically in 65 surgically removed glioma tissue and 21 peri-tumor tissues and 8 cases of normal brain tissues obtained from hematoma patients with cerebral trauma. Immunofluorescence, Western blot, and qRT-PCR were also used to verify immunohistochemical data. Adenosine P1 receptor ADORA1 and ADORA2A proteins were localized in the cell membrane and cytoplasm and ADORA1/ADORA2A immunoreactivity was significantly stronger in glioma and peri-tumor tissues that contained infiltrating tumor cells than in normal brain tissues (p < 0.05). The World Health Organization (WHO) grade III gliomas expressed even higher level of ADORA1 and ADORA2A. Western blot and qRT-PCR confirmed immunohistochemical data. Moreover, higher levels of ADORA1 and ADORA2A expression occurred in high-grade gliomas, in which incidence of epilepsy were lower (p < 0.05). In contrast, a lower level of ADORA1/ADORA2A expression was found in peri-tumor tissues with tumor cell presence from patients with epilepsy compared to patients without epilepsy (p < 0.05). The data from the current study indicates that dysregulation in ADORA1/ADORA2A expression was associated with glioma development, whereas low level of ADORA1/ADORA2A expression could increase susceptibility of tumor-associated epilepsy.

Keywords

ADORA1 ADORA2A Glioma Epilepsy Immunohistochemistry 

Notes

Acknowledgments

This study was supported in part by grants from the Scientific Research Foundation of State Education Ministry for the Returned Overseas Chinese Scholars (#2013.1792) and the Department of Science and Technology of Hunan Province, China (#2013FJ4367).

Compliance with Ethical Standards

Conflict of interest

The authors declared that there is no conflict of interest in this work.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee of Xiangya Hospital of Central South University (Changsha, Hunan, China) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Goodenberger ML, Jenkins RB (2012) Genetics of adult glioma. Cancer Genet 205(12):613–621CrossRefPubMedGoogle Scholar
  2. 2.
    Stewart L, Burdett S, Glioma Meta-analysis Trialists Group (GMT) (2002) Chemotherapy for high-grade glioma. Cochrane Database Syst Rev (4):CD003913. doi: 10.1002/14651858.CD003913
  3. 3.
    van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 6(5):421–430CrossRefPubMedGoogle Scholar
  4. 4.
    Thom M, Blumcke I, Aronica E (2012) Long-term epilepsy-associated tumors. Brain Pathol 22(3):350–379CrossRefPubMedGoogle Scholar
  5. 5.
    de Mendonca A, Sebastiao AM, Ribeiro JA (2000) Adenosine: Does it have a neuroprotective role after all? Brain Res Brain Res Rev 33(2–3):258–274CrossRefPubMedGoogle Scholar
  6. 6.
    Fredholm BB, Abbracchio MP, Burnstock G, Dubyak GR, Harden TK, Jacobson KA, Schwabe U, Williams M (1997) Towards a revised nomenclature for P1 and P2 receptors. Trends Pharmacol Sci 18(3):79–82CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, Leff P, Williams M (1994) Nomenclature and classification of purinoceptors. Pharmacol Rev 46(2):143–156PubMedPubMedCentralGoogle Scholar
  8. 8.
    Abbracchio MP, Burnstock G, Verkhratsky A, Zimmermann H (2009) Purinergic signalling in the nervous system: an overview. Trends Neurosci 32(1):19–29CrossRefPubMedGoogle Scholar
  9. 9.
    Boison D (2005) Adenosine and epilepsy: from therapeutic rationale to new therapeutic strategies. Neuroscientist 11(1):25–36CrossRefPubMedGoogle Scholar
  10. 10.
    Hamil NE, Cock HR, Walker MC (2012) Acute down-regulation of adenosine A(1) receptor activity in status epilepticus. Epilepsia 53(1):177–188CrossRefPubMedGoogle Scholar
  11. 11.
    Silva IR, Nehlig A, Rosim FE, Vignoli T, Persike DS, Ferrandon A, Sinigaglia-Coimbra R, Fernandes MJ (2011) The A1 receptor agonist R-Pia reduces the imbalance between cerebral glucose metabolism and blood flow during status epilepticus: could this mechanism be involved with neuroprotection? Neurobiol Dis 41(1):169–176CrossRefPubMedGoogle Scholar
  12. 12.
    Mohammad-Zadeh M, Mirnajafi-Zadeh J, Fathollahi Y, Javan M, Jahanshahi A, Noorbakhsh SM, Motamedi F (2009) The role of adenosine A(1) receptors in mediating the inhibitory effects of low frequency stimulation of perforant path on kindling acquisition in rats. Neuroscience 158(4):1632–1643CrossRefPubMedGoogle Scholar
  13. 13.
    Rosim FE, Persike DS, Nehlig A, Amorim RP, de Oliveira DM, Fernandes MJ (2011) Differential neuroprotection by A(1) receptor activation and A(2A) receptor inhibition following pilocarpine-induced status epilepticus. Epilepsy Behav 22(2):207–213CrossRefPubMedGoogle Scholar
  14. 14.
    Wagner AK, Miller MA, Scanlon J, Ren D, Kochanek PM, Conley YP (2010) Adenosine A1 receptor gene variants associated with post-traumatic seizures after severe TBI. Epilepsy Res 90(3):259–272CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Cunha RA (2008) Different cellular sources and different roles of adenosine: A1 receptor-mediated inhibition through astrocytic-driven volume transmission and synapse-restricted A2A receptor-mediated facilitation of plasticity. Neurochem Int 52(1–2):65–72CrossRefPubMedGoogle Scholar
  16. 16.
    Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LJ, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807–1812CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    de Groot M, Iyer A, Zurolo E, Anink J, Heimans JJ, Boison D, Reijneveld JC, Aronica E (2012) Overexpression of ADK in human astrocytic tumors and peritumoral tissue is related to tumor-associated epilepsy. Epilepsia 53(1):58–66CrossRefPubMedGoogle Scholar
  18. 18.
    Ravizza T, Boer K, Redeker S, Spliet WG, van Rijen PC, Troost D, Vezzani A, Aronica E (2006) The IL-1beta system in epilepsy-associated malformations of cortical development. Neurobiol Dis 24(1):128–143CrossRefPubMedGoogle Scholar
  19. 19.
    Detre S, Saclani JG, Dowsett M (1995) A “quickscore” method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 48(9):876–878CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Shamji MF, Fric-Shamji EC, Benoit BG (2009) Brain tumors and epilepsy: pathophysiology of peritumoral changes. Neurosurg Rev 32(3):275–284CrossRefPubMedGoogle Scholar
  21. 21.
    Boison D, Stewart KA (2009) Therapeutic epilepsy research: from pharmacological rationale to focal adenosine augmentation. Biochem Pharmacol 78(12):1428–1437CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Cumiskey D, Butler MP, Moynagh PN, O’Connor JJ (2007) Evidence for a role for the group I metabotropic glutamate receptor in the inhibitory effect of tumor necrosis factor-alpha on long-term potentiation. Brain Res 1136(1):13–19CrossRefPubMedGoogle Scholar
  23. 23.
    Stellwagen D, Beattie EC, Seo JY, Malenka RC (2005) Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J Neurosci 25(12):3219–3228CrossRefPubMedGoogle Scholar
  24. 24.
    Chen JF, Sonsalla PK, Pedata F, Melani A, Domenici MR, Popoli P, Geiger J, Lopes LV, de Mendonca A (2007) Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and “fine tuning” modulation. Prog Neurobiol 83(5):310–331CrossRefPubMedGoogle Scholar
  25. 25.
    Bauer A, Langen KJ, Bidmon H, Holschbach MH, Weber S, Olsson RA, Coenen HH, Zilles K (2005) 18F-CPFPX PET identifies changes in cerebral A1 adenosine receptor density caused by glioma invasion. J Nucl Med 46(3):450–454PubMedGoogle Scholar
  26. 26.
    Boison D (2008) The adenosine kinase hypothesis of epileptogenesis. Prog Neurobiol 84(3):249–262CrossRefPubMedGoogle Scholar
  27. 27.
    Hwang SL, Lieu AS, Kuo TH, Lin CL, Chang CZ, Huang TY, Howng SL (2001) Preoperative and postoperative seizures in patients with astrocytic tumours: analysis of incidence and influencing factors. J Clin Neurosci 8(5):426–429CrossRefPubMedGoogle Scholar
  28. 28.
    Sebastiao AM, de Mendonca A, Moreira T, Ribeiro JA (2001) Activation of synaptic NMDA receptors by action potential-dependent release of transmitter during hypoxia impairs recovery of synaptic transmission on reoxygenation. J Neurosci 21(21):8564–8571PubMedGoogle Scholar
  29. 29.
    Boison D (2008) Adenosine as a neuromodulator in neurological diseases. Curr Opin Pharmacol 8(1):2–7CrossRefPubMedGoogle Scholar
  30. 30.
    Melani A, De Micheli E, Pinna G, Alfieri A, Corte LD, Pedata F (2003) Adenosine extracellular levels in human brain gliomas: an intraoperative microdialysis study. Neurosci Lett 346(1–2):93–96CrossRefPubMedGoogle Scholar
  31. 31.
    Hargus NJ, Jennings C, Perez-Reyes E, Bertram EH, Patel MK (2012) Enhanced actions of adenosine in medial entorhinal cortex layer II stellate neurons in temporal lobe epilepsy are mediated via A(1)-receptor activation. Epilepsia 53(1):168–176CrossRefPubMedGoogle Scholar
  32. 32.
    Boison D (2012) Adenosine dysfunction in epilepsy. Glia 60(8):1234–1243CrossRefPubMedGoogle Scholar
  33. 33.
    Yu L, Frith MC, Suzuki Y, Peterfreund RA, Gearan T, Sugano S, Schwarzschild MA, Weng Z, Fink JS, Chen JF (2004) Characterization of genomic organization of the adenosine A2A receptor gene by molecular and bioinformatics analyses. Brain Res 1000(1–2):156–173CrossRefPubMedGoogle Scholar
  34. 34.
    Kobayashi S, Millhorn DE (1999) Stimulation of expression for the adenosine A2A receptor gene by hypoxia in PC12 cells. A potential role in cell protection. J Biol Chem 274(29):20358–20365CrossRefPubMedGoogle Scholar
  35. 35.
    Arslan G, Kull B, Fredholm BB (2002) Anoxia redistributes adenosine A(2A) receptors in PC12 cells and increases receptor-mediated formation of cAMP. Naunyn Schmiedebergs Arch Pharmacol 365(2):150–157CrossRefPubMedGoogle Scholar
  36. 36.
    Trincavelli ML, Costa B, Tuscano D, Lucacchini A, Martini C (2002) Up-regulation of A(2A) adenosine receptors by proinflammatory cytokines in rat PC12 cells. Biochem Pharmacol 64(4):625–631CrossRefPubMedGoogle Scholar
  37. 37.
    Trincavelli ML, Melani A, Guidi S, Cuboni S, Cipriani S, Pedata F, Martini C (2008) Regulation of A(2A) adenosine receptor expression and functioning following permanent focal ischemia in rat brain. J Neurochem 104(2):479–490PubMedGoogle Scholar
  38. 38.
    Fotheringham JA, Mayne MB, Grant JA, Geiger JD (2004) Activation of adenosine receptors inhibits tumor necrosis factor-alpha release by decreasing TNF-alpha mRNA stability and p38 activity. Eur J Pharmacol 497(1):87–95CrossRefPubMedGoogle Scholar
  39. 39.
    Melani A, Corti F, Cellai L, Vannucchi MG, Pedata F (2014) Low doses of the selective adenosine A2A receptor agonist CGS21680 are protective in a rat model of transient cerebral ischemia. Brain Res 1551:59–72CrossRefPubMedGoogle Scholar
  40. 40.
    De Sarro G, De Sarro A, Di Paola ED, Bertorelli R (1999) Effects of adenosine receptor agonists and antagonists on audiogenic seizure-sensible DBA/2 mice. Eur J Pharmacol 371(2–3):137–145CrossRefPubMedGoogle Scholar
  41. 41.
    Sofroniew MV (2009) Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci 32(12):638–647CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Lama G, Mangiola A, Anile C, Sabatino G, De Bonis P, Lauriola L, Giannitelli C, La Torre G, Jhanwar-Uniyal M, Sica G, Maira G (2007) Activated ERK1/2 expression in glioblastoma multiforme and in peritumor tissue. Int J Oncol 30(6):1333–1342PubMedGoogle Scholar
  43. 43.
    Aronica E, Gorter JA, Jansen GH, Leenstra S, Yankaya B, Troost D (2001) Expression of connexin 43 and connexin 32 gap-junction proteins in epilepsy-associated brain tumors and in the perilesional epileptic cortex. Acta Neuropathol 101(5):449–459PubMedGoogle Scholar
  44. 44.
    Wick W, Menn O, Meisner C, Steinbach J, Hermisson M, Tatagiba M, Weller M (2005) Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long? Onkologie 28(8–9):391–396PubMedGoogle Scholar
  45. 45.
    Dehnhardt M, Palm C, Vieten A, Bauer A, Pietrzyk U (2007) Quantifying the A1AR distribution in peritumoural zones around experimental F98 and C6 rat brain tumours. J Neurooncol 85(1):49–63CrossRefPubMedGoogle Scholar
  46. 46.
    Vercueil L (2011) Brain tumor epilepsy: a reappraisal and six remaining issues to be debated. Rev Neurol (Paris) 167(10):751–761CrossRefGoogle Scholar
  47. 47.
    Van Dycke A, Raedt R, Vonck K, Boon P (2011) Local delivery strategies in epilepsy: a focus on adenosine. Seizure 20(5):376–382CrossRefPubMedGoogle Scholar
  48. 48.
    Fredholm BB, Chen JF, Cunha RA, Svenningsson P, Vaugeois JM (2005) Adenosine and brain function. Int Rev Neurobiol 63:191–270CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Jun Huang
    • 1
  • Ming-Na Chen
    • 2
  • Juan Du
    • 2
  • Hao Liu
    • 2
  • Yu-Jiao He
    • 2
  • Guo-Liang Li
    • 2
  • Shu-Yu Li
    • 2
  • Wei-Ping Liu
    • 2
  • Xiao-Yan Long
    • 2
    Email author
  1. 1.Departments of Neurosurgery, Xiangya HospitalThe Central South UniversityChangshaChina
  2. 2.Departments of Neurology, Xiangya HospitalThe Central South UniversityChangshaChina

Personalised recommendations